Chemoprevention is the administration of agents to prevent induction of cancer, or to inhibit or delay its progression. 1 In prostatic neoplasia, the time from tumour initiation and progression to invasive carcinoma often begins in men in the fourth and fifth decades of life and extends across decades. This phenomenon represents a unique opportunity to arrest or reverse the process of carcinogenesis with the use of chemopreventive agents. For prostate cancer, as for other cancer targets, development of successful chemopreventive strategies requires suitable cohorts, reliable biomarkers for evaluating chemopreventive eYcacy, and well characterised agents. 1 Histopathologists have an important role in prostate chemoprevention. They define the high risk groups, recognise the surrogate end markers, and evaluate the morphological eVects of the agents on the prostate tissue specimens. Table 1 gives the target populations that can be considered for prostate cancer chemoprevention trials. 2 
Target populations for prostate cancer chemoprevention

TARGET POPULATIONS IDENTIFIED BY PREMALIGNANT LESIONS
High grade prostatic intraepithelial neoplasia (PIN) is the most likely precursor of invasive prostate cancer, originating from the ducts and acini, particularly those of the peripheral zone of the prostate gland. 3 The histopathological continuum that culminates in early invasive adenocarcinoma is divided into two gradeslow and high-replacing the previous three grade system; PIN1 is considered low grade, and PIN2 and 3 are considered high grade. High grade PIN has several features similar to prostate cancer. 3 PIN retains an intact or fragmented basal cell layer, unlike cancer, which lacks a basal cell layer. A recent consensus group determined that a small subset of basal cells houses the stem cell population. These cells are the presumptive site of origin of PIN and prostatic adenocarcinoma. 4 The exact connection between PIN and prostate specific antigen (PSA) is not known, and several problems concerning their interrelation are unresolved. Research has indicated that high grade PIN alone does not account for raised serum PSA levels. 5 The most common genetic alterations in PIN and prostate cancer are: the gain of chromosome 7, particularly 7q31; loss of 8p and gain of 8q; and loss of 10q, 16q, and 18q. Inactivation of tumour suppressor genes or overexpression of oncogenes in these regions may be important for the initiation and progression of prostate neoplasia. Foci of PIN and prostate cancer have a similar proportion of genetic changes, but the foci of carcinoma usually have more alterations. This supports the hypothesis that PIN is the most likely precursor of prostate cancer. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] High grade PIN has a high predictive value as a marker for carcinoma, and its identification in biopsy specimens warrants further search for concurrent invasive cancer. High grade PIN is found in approximately 3% of biopsies. Recognising that approximately 50% of men with high grade PIN on biopsy will be found to have carcinoma on repeat biopsy, the management of high grade PIN on biopsy may only apply to 50% of the men initially discovered with this finding. 16 
AFRICAN AMERICAN MEN: A TARGET POPULATION
Data reported from the USA indicate that both the prevalence and the extensiveness of high grade PIN are higher in African American men than in whites, and that this discrepancy starts as early as the third decade of age. In necropsy studies by Sakr et al, 17 extensive high grade PIN with diVuse involvement of the prostate gland was evident in 7% of African American men less that 50 years of age, compared with 2% of white men in the same age group. In the series of men undergoing radical prostatectomy for clinically localised prostate cancer, extensive high grade PIN was significantly and consistently higher in the African American cohort than in the white cohort. The diVerence was more evident in young patients and those with small, organ confined tumours. In a subset of patients with clinical stage T1c prostate cancer, extensive high grade PIN was identified in 33% of African Americans and 12% of whites. Moreover, in men with organ confined disease, both the Gleason score and the extensiveness of high grade PIN were strong predictors of biochemical recurrence. These findings suggest that an important role for high grade PIN in the development of clinically significant, potentially aggressive prostate cancer in African American men.
TARGET POPULATIONS IDENTIFIED BY GENETIC
FACTORS
Recent recognition that a predisposition to prostate cancer can be inherited has led to a search for specific genes associated with the disease. Through a study of families with three or more aVected first degree relatives, a region on the long arm of chromosome 1 (1q24-25) has been tentatively identified as containing a gene, HPC1, involved in the development of hereditary prostate cancer. This genetic defect on chromosome 1 occurs in one third of men with hereditary prostate cancer. This means that approximately 30-40% of hereditary cases may be caused by this mutation. Although only about one in 500 men have this defect, it represents a significant breakthrough in the identification of genetic markers. 18 Other predisposing loci have been reported. 19 For instance, a close link between loss of heterozygosity at chromosome 8p22 and local tumour progression has been found, indicating the presence of a tumour suppressor gene at this locus. Chromosome 16q24 harbours the E-cadherin gene. Alterations in this gene seem to be involved in determining the metastatic potential of the tumour. Another predisposing factor seems to be the length of CAG repeats on the androgen receptor. Men with prostate cancer have significantly shorter repeats than age matched men with benign prostatic hyperplasia. Also Japanese men, who have a low incidence of prostate cancer, have longer CAG repeats than whites.
TARGET POPULATIONS IDENTIFIABLE BY MOLECULAR FACTORS
Some molecular changes (such as a reduced expression of glutathione S-transferase (GST-) and an enhanced expression of telomerase activity) can be detected in prostates without cancer or PIN as well as at a distance from the preneoplastic and neoplastic lesions. [20] [21] [22] [23] Such changes might be interpreted as the onset (that is, initiation stage) of the development of prostatic neoplasia. 4 Under certain conditions the lesions characterised by molecular changes might be able to progress to a morphologically identifiable premalignant stage and may then, owing to severe genetic instability, result in a clone that has the ability to invade. Data related to the formation of DNA adducts in normal tissue adjacent to cancer in humans support this hypothesis. 24 25 According to Han et al, 26 the selective occurrence of a DNA adduct in the tissue of origin of carcinomas and preceding carcinoma development suggests a causal relation between adduct formation and prostate cancer development in testosterone plus oestradiol-17 treated rats. Table 2 shows the criteria for selecting intermediate biomarkers as surrogate endpoints in chemoprevention trials.
Surrogate endpoint biomarkers for clinical trials on prostate cancer chemoprevention
1 Table 3 reports the candidate surrogate endpoint biomarkers being used in chemoprevention studies on prostate cancer. 27 28 In the process of defining a surrogate endpoint biomarker (SEBM), two considerations play a role. The first concerns properties that the SEBM should have; the second relates to the phase of oncogenic progression that the SEBM is intended to monitor.
An eVective SEBM should allow sensitive detection and precise characterisation of oncogenic progression. This implies that the SEBM should be an objectively measurable entitythat is, allow a numerical assessment. One may define a progression curve spanning the range from normal tissue to an infiltrating lesion. The state of a given case would be reflected by the value of a progression index indicating the case position along the progression curve. 29 Efficacy of a chemopreventive intervention then would be monitored by changes in the value of the progression index. Even a small diVerence in progression or regression should be clearly reflected in the value of the progression index. The sampling requirements for a statistically valid detection of change must be firmly established. Tissue sampling requirements should be such that the procedure can be kept minimally invasive so that repeat biopsies are feasible.
The progression index should represent tissue characteristics that are reversible so that not only progression but also halted progression or true regression can be observed. The progression assessment should be responsivethat is, the eVects of chemopreventive intervention should be reflected in the progression index after a short time. For example, tissue architectural changes concomitant with oncogenic progression-such as the disruption of the basal cell layer in PIN lesions, multiple layering of the secretory epithelium, or the assessment of number, size, and morphology of capillaries in the vicinity of PIN lesions-may take weeks or months to reflect a regressive eVect. However, changes in the spatial and statistical distribution of nuclear chromatin, or microphotometric monitoring of the amounts of certain gene products by immunohistochemistry, may be expressed and measurable within days. [29] [30] [31] Ideally, the micromorphometric or microphotometric characteristics entered into the value of the progression index should undergo a monotonic trend from normal tissue to infiltrating disease. If that is not possible, additional criteria must be defined so that an observed progression can unequivocally be assigned to a certain segment on the progression curve. Various micromorphometric entities have been found eminently suitable for the establishment of a progression curve for ductal carcinoma in situ of the breast 32 33 and solar keratosis of the skin. 34 In the prostate, both histometric entities-such as the degree of disruption of the basal cell layer, 35 and karyometric variables, 36 37 again derived from the nuclear chromatin texture 31 -provide a well defined progression curve for PIN lesions. Thus, for the assessment of lesion progression, suitable procedures have already been developed. 34 There is, unfortunately, an almost total lack of quantitative micromorphometric studies of clinical materials from chemoprevention trials.
In chemoprevention one is usually facing a situation where tissue alterations or karyometric changes are still at the early stage of oncogenic progression, and thus are subtle. It is therefore not surprising that in a randomly sampled cell population not all cells are uniformly progressed, as was also found in the studies cited above. Rather, only a certain proportion of nuclei may show the eVects of oncogenic progression. The progression index curve was therefore defined on the basis of data from the 10% most progressed nuclei classified as showing signs of actinic damage. This approach has been found to allow sensitive detection of the eYcacy of chemopreventive agents. It shows these eVects undiluted by the values seen in the bulk of nuclei in a cell population which did not deviate from normal in the first place.
There is a need to examine the sampling protocol carefully with respect to adequacy of sample size, representativeness for the condition of the lesion and potential local heterogeneity, and finally, for inherent biases. For example, a protocol may call for two biopsies from the centre of a lesion before and following a chemopreventive regimen. This may automatically restrict sampling to lesions that are still recognisable after intervention. Their small size and the disruption induced by biopsy make this evaluation of chemopreventive eYcacy difficult for high grade PIN lesions. While it constitutes a stringent test for eYcacy, the requirement may induce a bias by not considering lesions that responded to intervention.
An SEBM derived from a topographically much more widely expressed phenomenon, such as the malignancy, or PIN associated changes in the chromatin of nuclei from histologically normal appearing tissue, would not have this problem. 31 Even an ultrasound guided needle biopsy may not provide a sample that directly reflects regression at the previously biopsied site. There may be eVects of the disturbance of the tissue by the previous needle insertion, and one may also have to consider local grade heterogeneity, even in a small lesion.
A case can therefore be made for the need for a placebo arm in such studies. Image analytical procedures result in quantitative numerical data, and usually there would not be a need to provide a placebo arm to rule out subjectivity in the evaluation. But the above sampling problems might well not allow an unequivocal assessment of eYcacy, unless compared statistically with the placebo arm results. On the other hand, chromatin texture assessment is a highly sensitive procedure, and one has to con- The second set of considerations relates to the events in oncogenic progression that an SEBM should monitor. Consider as a general interval of interest the range from an initiating event, at the genomic/molecular level at the beginning, and infiltrating disease with potential for metastasis at the end. One has, in the sequence of oncogenic progression, to distinguish between necessary but not suYcient events, and events that clearly form part of an inevitable, deterministic continuation to infiltrating disease. A molecular event, at the gene level, may well be a crucial initiating step towards a malignancy. Thus it may be a necessary event. But it is by no means clear, and even improbable, that every such event will inevitably result in an infiltrating lesion-in many instances it is insuYcient.
On the other hand, it also is not a reversible event. A progression measure based on detection of such an event may therefore always detect its presence, even if a chemopreventive regimen had successfully halted, and possibly partially reversed, subsequent oncogenic progress. Molecular genetic probes can provide a profile revealing the set of genomic defects relating to oncogenic progression. For an individual nucleus each such marker provides definitive detection-which of course is a binary result-rather than being an index measuring continuous change.
Changes in the nuclear chromatin texture oVer the advantage that they reflect a reversible phenomenon, and that they oVer detection even before histopathological assessment could discern change. Chromatin changes reflect processes that occur later than the earliest initiating molecular events. They occur at a phase in oncogenic progression close to the evolution of a deterministic process and can be closely followed up to the occurrence of microinfiltration. It is not clear even now whether a point of deterministic and inevitable progression to infiltrating disease can be defined, even though numerous necessary preceding events have been identified.
Ploidy measurement presents a case in point. 36 37 A highly aneuploid lesion, with its obvious genomic instability, ranks high as a measure of lesion progression. A high level of aneuploidy, though, may not be very suitable as an SEBM. If lowered ploidy values in a cell population undergoing progression were taken as a marker for regression one may have diYculty in interpreting the biological basis. Does this mean that nuclei with very severe genomic instability have disappeared, for example because of enhanced induction of apoptosis? Or does it mean that a clone of lower ploidy is in the ascendancy? Such clones may, in fact, have higher potential for invasion, so that the SEBM suggests regression when in fact exactly the opposite is taking place. There are, fortunately, several micromorphometric and microphotometric entities that may make good SEBMs. The averaged deviation of chromatin texture features from normal is a useful measure. The distribution of this index among the nuclei of a lesion before and after chemopreventive intervention may lend itself well to defining an SEBM.
In the search for suitable measures of oncogenic progression an argument could be put forward for the choice of entities that manifest themselves immediately before, or during, the development of a histopathologically recognisable lesion. The phase of oncogenic progression from the initiating molecular event to the point where micromorphometric changes are detectable is still largely unexplored. It is likely that there are several pathways-possibly a substantial number-leading to progressive change, and sequential development of multiple genomic defects may play an important role. However, it is not clear at this time whether progression might not occur even without the induction of a specific genomic defect in such a sequence. Cellular metabolism, in principle, involves a complex system with numerous non-linear processes, controlled by a myriad of feedback and control mechanisms that, once disturbed, might well be subject to derailment in various diVerent ways. Measurements monitoring tissue changes further along progression may therefore oVer a safeguard for detecting progression even if a given genomic event was not observed.
Drug treatment and prevention
Several potentially chemopreventive drugs have been studied in carcinogenesis models in the prostate both in vitro and in vivo. Table 4 shows a selection of mechanisms and agents for intervention and prevention of prostate carcinogenesis. 38 
HORMONAL MANIPULATIONS
Androgens are pivotal regulators of prostate growth, diVerentiation, and function. Their actions are believed to be involved in prostate cancer development. 39 The androgen signalling pathway in the prostate gland is therefore one of the possible sites of intervention in prostate cancer prevention eVorts. 2 39 The central element of androgen signalling in the cell is the androgen receptor, a member of the superfamily of nuclear receptors. Binding of androgen to its ligand binding domain transforms the receptor to an active transcription factor that regulates gene expression by interacting with specific regulatory elements in the promoters of the genes. In addition to this genomic action, the androgen receptor also interacts with other signalling pathways through protein-protein interaction. It is not only the action of androgen hormones, but also the interactions of growth factor and protein kinase A signalling pathways, that can induce activation of androgen receptor. Moreover, these ligand dependent activators act synergistically together with low concentrations of androgens.
-Reductase inhibition
Finasteride acts as a competitive and specific inhibitor of 5 -reductase, resulting in suppression of serum and intraprostatic dihydrotestosterone concentration to castrate levels, with subsequent reduction in prostatic size. 5 -Reductase inhibition results in a significant increase in intraprostatic testosterone levels, allowing testosterone mediated functions, including libido, potency, and male musculature, to remain largely unaVected. Finasteride is approved for treatment of symptomatic benign prostatic hyperplasia. It is associated with a 50% reduction in PSA, which is significantly less than the reduction associated with medical or surgical castration. Tumour growth has been suppressed by 5 -reductase inhibition in animal and human tumour lines. An attractive feature of finasteride is its excellent safe profile, making it a reasonable candidate for chemoprevention trials in the general and high risk target populations. 40 The modest morphological changes induced by finasteride raise concern that this drug may not be suYciently eVective to prevent or reverse high grade PIN or prostate cancer.
Antiandrogens
Antiandrogens competitively bind to androgen receptors at the target cell level. This class of agents blocks testicular and adrenal androgens. Antiandrogens are currently approved for use in combination treatment with a luteinising hormone releasing hormone analogue for complete androgen blockade in the management of prostate cancer. Bicalutamide and flutamide are non-steroidal antiandrogens that selectively inhibit androgen receptors, including those in the prostatic cytoplasm. 41 These agents have no androgenic or progestational activity, and are able to counteract testicular and also adrenal androgens eVectively. Antiandrogens and 5 -reductase inhibitors, if used alone or in combination to prevent or reverse high grade PIN or prostate cancer, may oVer a quality of life advantage over other androgen ablation methods because they do not reduce serum testosterone and therefore do not have a marked inhibitory aVect on libido and potency.
Other hormonal agents
Continuous administration of high doses of luteinising hormone releasing hormone analogues causes inhibition of luteinising and follicle stimulating hormone release with subsequent suppression of testosterone production at the testicular level. The major side eVects of these agents include impotence, loss of libido, atrophy of the reproductive organs, and hot flushes. These potent agents are not suitable for chemoprevention in the general population; however, in high risk target populations such as those with high grade PIN, perhaps three to six months of treatment could significantly improve outcome, outweighing the side eVects incurred during the treatment interval.
Combining androgen ablation agents may decrease prostate cancer risk in target populations such as those with high grade PIN. Combination treatment may decrease overall side eVects by lowering eVective dosages and shortening treatment duration. A non-steroidal antiandrogen agent could be used in combination with a 5 -reductase inhibitor in men who want potency preserved. Combination treatment with a luteinising hormone releasing hormone analogue and an antiandrogen would be an option for men in whom potency is not a concern.
Other than its cardiovascular complications, oestrogens have been associated with fluid retention, gynaecomastia, and loss of libido and potency, side eVects that probably outweigh a chemopreventive benefit of these agents. 42 
RETINOIDS
Vitamin A and its products, retinoic acid and the retinoids, are essential in the normal control of epithelial cell growth and cellular diVerentiation. They appear to act in a hormone-like way, targeting specific organs, of which the eye and the liver are the best documented. It has long been known that they are important for the maintenance of a normal germinal epithelium and are necessary for the diVerentiation of prostate glandular epithelium. 43 There is interdependence between vitamin A and zinc. This is most clearly demonstrated in patients with poor dark adaptation, in which full night vision is not restored until both elements are replaced, the presence of either one alone being insuYcient. A reciprocal relation between serum zinc and serum vitamin A in patients with prostate cancer has not been demonstrated, suggesting that this interdependence may be disrupted in such patients. There is abundant in vitro experimental evidence showing that vitamin A has a beneficial eVect in preventing prostatic carcinogenesis. 44 45 Importantly, in these experiments trans-retinoid and retinoid enhance normal apoptotic activity. That retinoid supplements do work eVectively in restoring normal function is seen in patients with acne, the androgen dependent skin disease, when they are treated in this fashion over prolonged periods. SuYciently large experimental studies on dietary supplementation, however, remain to be performed.
VITAMIN D
An inverse correlation between ultraviolet radiation, the principal source of vitamin D, and prostate cancer mortality has been shown in epidemiological studies. 46 52 53 It thwarts cell proliferation by inhibiting polyamine synthesis. Polyamines are normal cell constituents important for cell proliferation. The enzyme ornithine decarboxylase is responsible for the first and rate limiting step in mammalian synthesis of polyamines. An increase in ornithine decarboxylase activity is thus necessary for cell proliferation. Difluoromethylornithine is a suicide substrate that inactivates ornithine decarboxylase by irreversible binding to it. Difluoromethylornithine may be especially eVective in the prevention of prostate cancer because the prostate has very high concentrations of polyamines and polyamine synthetic enzymes. Kadmon et al have found chemopreventive activity in Dunning R3327 rat prostatic carcinoma models. 52 There are several reasons, including toxicity, that would make diYcult to mount a large scale study of this agent.
ANTIANGIOGENIC AGENTS
There are two distinct phases during prostatic carcinogenesis with regard to tumour blood vessel development. 54 55 During the first or prevascular phase, which may persist for years, cells that have undergone some but not all of the transformation steps undergo a limited amount of net growth, producing premalignant lesions such as PIN. Once this angiogenic phase is reached, new blood vessel development is greatly enhanced within the cancer. It is this enhanced tumour angiogenesis which allows these cancers both to grow continuously and to metastasise. Understanding the events controlling angiogenesis could allow the development of new therapeutic approaches to prevent neoplastic progression as well as to induce the regression of cancers and their precursors. 54 Linomide 56 is a low molecular weight, water soluble agent with excellent oral absorption. Treatment with linomide has antiangiogenic abilities against a series of rat and human prostatic cancer xenografts growing in vivo. Using the Matrigel in vivo angiogenesis assay, daily oral linomide (25 mg/kg/d) inhibits angiogenesis induced by tumour necrosis factor , acidic fibroblast growth factor, basic fibroblast growth factor, and vascular endothelial growth factor.
Using an N-methylnitrosourea initiation-androgen promotion model, linomide was given for at least one year without major toxicity, while inhibiting the development of seminal vesicle/prostate cancer in male rats by > 50%. Dose-response analysis showed that a linomide blood level of 50-100 µM is optimal for such chemoprevention. In addition, linomide treatment at a dose of 25 mg/kg/d was able to inhibit by approximately 60% the incidence of N-methylnitrosourea induced mammary carcinogenesis in female rats, and by approximately 50% that induced by 7,12-dimethylbenz( )anthracene.
Diet intervention and prevention
Epidemiological studies support the hypothesis that the composition of the diet has a potential influence on prostate carcinogenesis. Some of the factors that may make important contributions to overall prostate cancer risk are selenium, dietary fat, and phyto-oestrogens. 57 
SELENIUM
The nutritionally essential trace element selenium was first associated with cancer risk in the late 1960s. Since then, a substantial body of research has elucidated functions of selenium in normal metabolism and documented the cancer prevention potential of selenium supplementation in animals. Selenium compounds have been shown to have antitumorigenic activities in animal models when the drug is given at levels greater than those associated with nutritional needs. Several hypotheses have been proposed to explain the inhibition of tumorigenesis by supplemental selenium, including protection against oxidative damage involving the function of selenium as an essential component of the antioxidant enzyme glutathione peroxidase, alterations in carcinogen metabolism, production of cytotoxic selenium metabolites, inhibition of protein synthesis, inhibition of specific enzymes, and stimulation of apoptosis. 58 59 Geographical studies suggest an inverse relation between selenium status and cancer incidence in humans. In a study of the ecological relation of environmental selenium levels (forage crop selenium) and county levels of cancer mortality in the USA, cancer mortality rates were significantly lower for total cancer and cancers of the lung, colon and rectum, bladder, oesophagus, pancreas, breast, ovary, and cervix in counties with intermediate selenium or high selenium levels compared with low selenium counties. A prospective study among 50 000 health professionals has shown selenium to be associated with lower risk; a nested case-control study in which toenail selenium was used to assess selenium status indicated that raised selenium levels are associated with a 50% decrease in prostate cancer risk. 60 Two smaller studies 61 62 yielded similar evidence. On the other hand, a prospective study conducted in Finland 63 showed little evidence of such eVects (selenium in this latter study was represented by serum concentrations).
A study of the incidence of prostate cancer has shown that selenium supplementation decreases the incidence in men with a history of non-melanoma skin cancer. 64 This study, a clinical trial reported by Clark et al, 64 provides the strongest human based evidence that selenium protects against prostate cancer. That trial indicated that 200 µg/day of selenium supplementation, with selenium delivered in yeast, decreases prostate cancer risk by approximately 60%. However, as prostate cancer was one of several secondary endpoints considered (the study was designed to evaluate the protective impact of selenium against basal and squamous cell skin cancers within a population characterised by previous skin cancer and by residence in regions with low selenium forage levels) the finding needs to be replicated. 57 
DIETARY FAT
The higher amounts of dietary fat in western Europe, the USA, and Canada have been suggested to explain the higher prostate cancer mortality in these populations. 65 66 Overall, a diet in which 40-60% of energy comes from fat appears to increase the relative risk of prostate cancer by a factor of 1.6 to 1.9. This association appears strongest for fat from meat. 65 There is evidence that a population with a lifetime pattern of low fat consumption has a lower risk of prostate cancer. To date no definitive study has been conducted to determine if a change to a low fat diet after years of a diet high in fat will lower prostate cancer risk.
The molecular mechanisms linking dietary fat to prostrate cancer biology, however, are not completely understood. Diets high in fat are associated with an increased production of sexual hormones. Black African men fed a Western diet have an increased excretion of both androgens and oestrogens, while the opposite trend was shown in African American men fed a vegetarian diet. 65 66 Therefore, dietary fat is presumably converted to androgens, leading to increased androgen stimulation of the prostate. This may translate into an increased risk of hormonally induced tumours.
Animal fats are typically rich sources of arachidonic acid and this fatty acid is converted into a wide range of powerful compounds, including prostaglandins and leukotrienes. 65 66 It has been shown that the PC3 and LNCaP cell lines convert arachidonic acid into the 5-lipoxygenase product, 5-hydroxyeicosatetraenoic acid (5-HETE). When the formation of 5-HETE is abolished, human prostate cancer cells enter apoptosis in a very short time, usually minutes, and are dead within two hours. Exogenous 5-HETE can prevent death of these cancer cells. These findings indicate that lipoxygenase inhibition has a role in the development of prostate neoplasia and that 5-HETE is a potent survival factor for human prostate cancer cells. 67 
PHYTO-OESTROGENS AND DIETS HIGH IN FRUITS AND VEGETABLES
Isoflavonoids, flavonoids, and lignans are phyto-oestrogens derived from soya, tea, fruits, and vegetables. They have been proposed as chemopreventive agents in Asian men, in whom the incidence of prostate cancer is much lower than in Western populations. 68 Lower incidences have also been noted in vegetarians compared with omnivorous men. Oestrogen antagonistic activity has been described for some of these compounds, in addition to a weak oestrogenic activity. Furthermore, the lignan enterolactone and the soya derived isoflavone, genistein, are inhibitors of several steroid metabolising enzymes such as aromatase, 5 -reductase, and 17 -hydroxysteroid dehydrogenase. Genistein is a potent inhibitor of tyrosine kinases and, along with flavonoids such as kaempferol and apigenin, is also an inhibitor of topoisomerases I and II, enzymes that are crucial to cell proliferation. Genistein is also an inhibitor of angiogenesis. In many experimental in vivo and in vitro models, including those for cancer of the prostate, isoflavonoids, flavonoids, and lignans inhibit growth. It is estimated that the traditional Japanese diet provides a man with approximately 20 mg of isoflavones a day, compared with less than 1 mg a day provided by a typical Western diet. This is reflected in the high mean plasma concentration of genistein in Japanese men (180 ng/ml), compared with a level of < 10 ng/ml for Western men. 69 70 It is possible that other agents found within fruits and vegetables are protective. One large prospective study has provided evidence that lycopene, a carotenoid with substantial antioxidant activity, is associated with decreased risk of prostate cancer; one other study conducted in Hawaii was noteworthy for its failure to observe this eVect. 71 There may have been inadequate variance in lycopene intake in this population to allow for detection of protective eVects.
One of the few positive outcomes of the tocopherol carotene chemoprevention trial, conducted among some 29 000 heavy smokers in Finland, was a 30% reduction in prostate cancer incidence by tocopherol or vitamin E. 63 72 This reduction was statistically significant and a reduction of this magnitude would be clinically significant as well. 72 This finding needs to be tested in another large clinical trial, as it was an unanticipated consequence of the trial.
Animal models in defining eYcacy of chemoprevention agents against prostate cancer Detection of inhibitory eVects on de novo prostate cancer development requires a high cancer incidence and similarity of induced tumours to human prostate carcinomas. The following animal models have produced high incidences of multifocal prostate adenocarcinoma: transgenic mice with oncogenes expressed in a prostate specific fashion; Noble rats that have been treated chronically with combination of 17 -oestradiol and testosterone; and Wistar or F344 rats treated sequentially with a single injection of N-methyl-N-nitrosourea (MNU) and chronic administration of testosterone. PIN most often occurs in the first two models, and metastases are frequent in some transgenic models and the MNU-testosterone model. 47 73-76 The chemopreventive eYcacy of a series of agents using a model in which hormone dependent prostate cancer is induced in the Wistar-Unilever rat. 77 This is achieved by sequential treatment with an antiandrogen (cyproterone acetate), and androgen (testosterone propionate) and a direct acting chemical carcinogen (N-methyl-N-nitrosourea), followed by chronic androgen stimulation (testosterone). This regimen reproducibly induces a high incidence (< 75%) of prostate cancer, with no gross toxicity and a low incidence of neoplasia in the seminal vesicles and other non-target tissue. Dehydroepiandrosterone (DHEA) and 9-cis-retinoic acid (9-cis-RA) are the most active chemopreventive agents identified to date. DHEA inhibits the induction of prostate cancer when administration is started before carcinogen exposure, and when it is delayed until incipient neoplastic lesions are present. Chronic administration of 9-cis-RA starting before carcinogen exposure is highly eVective in the chemoprevention of prostate cancer. Liarozole fumarate confers modest protection against induction of prostate cancer, whereas N-(4-hydroxyphenyl)retinamide (4-HPR),
-difluoromethylornithine, DL--tocopherol acetate (vitamin E), oltipraz, and L-selenomethionine are inactive. The diVerential activity of 9-cis-RA and 4-HPR suggests the ligand specificity may be a determinant of retinoid action in prostate cancer chemoprevention.
The eVects of long term androgen deprivation on androgen signalling have been investigated in the LNCaP cell culture system. 78 Long term culture in a steroid-free medium results in a subline showing a hyperreactive androgen receptor characterised by increased androgen receptor expression and enhanced androgen receptor transcriptional activity in an environment with low levels of androgen hormones. It is not yet clear if similar changes also occur in normal or premalignant prostate epithelial cells and are thus relevant for prevention trials assessing interference with androgen hormone signalling.
Chemoprevention strategies
The most eYcient strategy for developing a chemoprevention programme is to perform two clinical trails concurrently, each based on the modulation of high grade PIN but in diVerent target populations. 38 57 In patients with high grade PIN associated with prostate cancer, a prospective, double blind, placebo controlled chemoactive pilot study designed to measure the response of a potential chemopreventive agent in the period (three to six weeks) before radical prostatectomy could easily be performed. Androgen deprivation treatment is commonly used in this population to downsize the prostate before radical prostatectomy. This study may provide information regarding the eVectiveness of proposed agents on surrogate endpoint biomarkers, premalignant lesions, and cancer. In particular, such an investigation would determine the response of PIN to the agent in whole mounted radical prostatectomy specimens. In some preliminary investigations it has been shown that there is a marked decrease in the prevalence and extent of PIN in prostates after androgen deprivation treatment, as compared with untreated prostates. 79 This is accompanied by regressive changes in the secretory epithelium. Apoptotic bodies are more often seen in the treated normal prostate, PIN, and prostate cancer than in untreated cases. This suggests that androgen ablation induces epithelial regression by enhancing apoptosis. The low proliferating cell nuclear antigen (PCNA) and Ki67 related values and the absence of mitoses in PIN as well as in normal prostate and prostate cancer in the treated cases indicates suppressed proliferation activity as a consequence of androgen deprivation treatment.
11 80 81 It has be reported that angiogenesis is inhibited in prostate lesions when total androgen ablation induces cell regression and activation of the apoptosis type of cell death. 54 Consequently, the epithelial cells are blocked from expressing, producing, or exporting angiogenic molecules. All these findings indicate that the dysplastic prostatic epithelium is hormone dependent.
A short term prospective, double blind, placed controlled phase II chemopreventive trial with cancer as an endpoint could be done in patients with high grade PIN without cancer. Chemoprevention trials designed to reverse high grade PIN may be confounded by the presence of underlying but undetected prostate cancer. This diYcult problem is addressed by requiring a second biopsy with negative findings for cancer before entry into the study (preferably sextant biopsies with special attention to areas of abnormality on ultrasonogram or digital rectal examination), and by including enough subjects in the study and control groups to equalise the risk of coexistent cancer between the two groups. PIN is routinely monitored by repeat biopsy in contemporary urological practice. Periodic re-evaluation would be necessary, including physical examination, rebiopsy, and evaluation of surrogate intermediate endpoint biomarkers. If subsequent biopsy reveals prostate cancer, these patients need definitive treatment. Those with PIN or no malignancy need continued observation.
38
Examples of clinical chemoprevention studies Table 5 reports agents, the treatment periods, and the primary endpoints used in clinical chemoprevention studies sponsored or funded by the National Cancer Institute. 82 
TRIAL OF SELENIUM AMONG HIGH GRADE PIN PATIENTS
A promising and eYcient option for testing selenium is to evaluate it in a chemoprevention trial focused on a population at high risk of prostate cancer. 83 Men with high grade PIN clearly comprise such a population. 57 83-85 The three year incidence of prostate cancer among men with high grade PIN has been estimated to be as high as 50% [84] [85] [86] ; men with high grade PIN are clearly appropriate subjects for prostate cancer prevention trials.
A randomised placebo controlled trial of selenium for chemoprevention of prostate cancer among men diagnosed with high grade PIN would be scientifically attractive and cost eYcient. Selenium is low in toxicity at a dose of 200 µg/day. In Clark's chemoprevention trial, no instances of serious toxicity were noted. 64 After initial biopsy identifying high grade PIN, it will be necessary to rebiopsy before randomisation to lessen the probability that the subject has prostate cancer missed by the first biopsy. 57 83-86 The primary study outcome should be progression of high grade PIN to prostate cancer. Secondary endpoints of proliferation and apoptosis, and changes in ductal, glandular, cellular, and nuclear morphometry-including nuclear and nucleolar area, DNA content, and chromatin pattern and distribution [29] [30] [31] -will also be informative and useful.
The University of Arizona, working with the Southwest Oncology Group, has embarked upon a chemoprevention trial with a placebo controlled, double blinded design, comparing 200 µg selenium as 1-selenomethionine with placebo. Each participant will be treated for up to three years. The final prostate biopsy will be conducted at 36 months. The target sample size is 470 randomised patients, 235 per arm, which will require initially enrolling 1125 patients. The power will be 0.90, with an level of 0.05, two sided, to detect a one third reduction in the three year incidence rate of prostate cancer.
Side eVect diVerences will be monitored throughout the study. Power with even 100 patients randomised exceeds 90% to detect a diVerence in side eVect rates of 15 percentage points if the placebo rate is around 5% and 20 percentage points if the placebo rate is in the 10-20% range, assuming 100 patients on selenium and 100 on placebo. As much larger numbers of patients will be under observation as the study progresses, sensitivity to side eVects will be even greater. The primary outcome variable-three year prostate cancer incidence rate-will be analysed using standard statistical techniques for dichotomous variables.
PROSTATE CANCER PREVENTION TRIAL
The National Cancer Institute and several of its cooperative oncology groups are sponsoring a randomised, double blind, placebo controlled trial to determine of 5 -reductase inhibition will reduce the incidence of prostate cancer (phase III trial of finasteride). 87 The primary endpoint is prostate cancer as determined by biopsy, and the study has a 92% power to detect a 25% diVerence between the finasteride and placebo arms. The prostate cancer prevention trial (PCPT) opened for participant enrolment in October 1994. Exactly three years later, the study met its enrolment goal: 18 882 men aged over 55 years, with normal digital rectal examination and serum PSA concentrations of < 3.0 ng/ml, were randomised to take finasteride (5 mg/day) or placebo (1 tablet/ day). Digital rectal examination and PSA were done yearly. When digital rectal examination is abnormal or PSA rises to > 4.0 ng/ml, a biopsy is recommended. Because of the eVect finasteride has on PSA, the PSA value has been indexed to equalise the number of biopsies in both arms. At seven years all survivors will undergo a sextant biopsy to determine the period prevalence of prostate cancer. This 10 year study will achieve its primary endpoint in 2004. A multidisciplinary group of PCPT investigators is currently focusing upon methods to maintain adherence of all study participants over the course of the next seven years of study. As the majority of prostate cancer diagnoses are expected during the final year of the study, no interim analyses are planned.
Conclusions
Chemoprevention is most eVective in the early stages of cancer formation when reversibility may be feasible. 82 In particular, for prostate cancer, as for other cancer targets, development of successful chemopreventive strategies requires suitable cohorts, reliable biomarkers for evaluating chemopreventive eYcacy, and well characterised agents (table 6) . Table 6 Summary statements 1 . Premalignant lesions, such as high grade prostatic intraepithelial neoplasia, identify patients at high risk for development of prostatic carcinoma, and these are ideal target populations for chemopreventive trials. 57 2. Because of the long time period for the process of carcinogenesis and large cohort required for an evaluable study, cancer incidence is not usually a feasible endpoint for chemoprevention clinical studies. Thus identification and characterisation of intermediate biomarkers and their validation as surrogate endpoints for cancer incidence in clinical chemoprevention trials are significant components in the development of chemoprevention strategies. 3. Animal models are crucial in testing the preclinical eYcacy of chemoprevention agents. 88 Several animal models are used for the detection of chemo-inhibitory eVects in various stages of prostate cancer development. Human prostate cancer xenografts in immunocompromised mice and transplantable rodent prostate carcinomas (ie, the Dunning rat tumour lines) can be used to assess inhibition of tumour growth. 89 4. Chemoprevention trials usually use natural or synthetic agents at doses that have minimal, if any, adverse eVects. However, these trials may have diVerent acceptable toxicity tolerance levels according to the agent under investigation and the relative risk of cancer in the study population.
